A Novel Dose-adjustment Protocol for Interrupted Subcutaneous Immunotherapy in Children with Allergic Rhinitis

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2024 Jul 3

PMID 38957931

Authors

Min Pan

Jianrong Xue

Affiliations

Soon will be listed here.

Abstract

To assess the effectiveness and safety of a new protocol for adjusting doses during interrupted subcutaneous immunotherapy maintenance, exceeding an 8-week interval, with mite allergen injections in children with allergic rhinitis. 194 children with allergic rhinitis who underwent subcutaneous immunotherapy and experienced interruptions lasting more than 8 weeks during maintenance were enrolled. Following the adoption of a novel dose-adjustment protocol, a real-world study was conducted. After 3 years of subcutaneous immunotherapy, the novel group exhibited a significant reduction in allergy symptoms compared with baseline. Systemic reactions related to the novel protocol did not significantly increase. The novel protocol was deemed safe and effective, offering advantages of time savings and reduced burdens.

References

Niggemann B, Jacobsen L, Dreborg S, Ferdousi H, Halken S, Host A . Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006; 61(7):855-9. DOI: 10.1111/j.1398-9995.2006.01068.x. View

Xi L, Cao F, Zhang Y, Zhang L . Severity of nasal obstruction can predict the anxiety status of patients with allergic rhinitis but not patients with vasomotor rhinitis. Int Forum Allergy Rhinol. 2016; 6(11):1196-1203. DOI: 10.1002/alr.21802. View

Koca Kalkan I, Ates H, Aksu K, Yesilkaya S, Topel M, Cuhadar Ercelebi D . Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic. World Allergy Organ J. 2021; 14(7):100558. PMC: 8185179. DOI: 10.1016/j.waojou.2021.100558. View

Violan V, Gandolfo Cano M, Vicente E, Trujillo M, Gonzalez Mancebo E . Influence of the COVID-19 pandemic on the prescription and adherence to allergen-specific immunotherapy. Clin Exp Allergy. 2022; 52(7):916-917. DOI: 10.1111/cea.14115. View

Cheng X, Hu J, Luo L, Zhao Z, Zhang N, Hannah M . Impact of interventions on the incidence of natural focal diseases during the outbreak of COVID-19 in Jiangsu Province, China. Parasit Vectors. 2021; 14(1):483. PMC: 8449989. DOI: 10.1186/s13071-021-04986-x. View

Han X, Krempski J, Nadeau K . Advances and novel developments in mechanisms of allergic inflammation. Allergy. 2020; 75(12):3100-3111. DOI: 10.1111/all.14632. View

Ansotegui I, Melioli G, Canonica G, Caraballo L, Villa E, Ebisawa M . IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 2020; 13(2):100080. PMC: 7044795. DOI: 10.1016/j.waojou.2019.100080. View

Liu W, Zeng Q, He C, Chen R, Tang Y, Yan S . Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis. Pediatr Allergy Immunol. 2020; 32(1):86-91. DOI: 10.1111/pai.13332. View

Bilo M, Braschi M, Piga M, Antonicelli L, Martini M . Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic. J Allergy Clin Immunol Pract. 2020; 9(2):702-708. PMC: 7690271. DOI: 10.1016/j.jaip.2020.11.030. View

10.

Halken S, Larenas-Linnemann D, Roberts G, Calderon M, Angier E, Pfaar O . EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017; 28(8):728-745. DOI: 10.1111/pai.12807. View

11.

Wang C, Bao Y, Chen J, Chen X, Cheng L, Guo Y . Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update. Allergy Asthma Immunol Res. 2022; 14(6):604-652. PMC: 9709690. DOI: 10.4168/aair.2022.14.6.604. View

12.

Kim J, Jang M, Kim D, Park S, Han D . Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison. J Allergy Clin Immunol Pract. 2021; 9(12):4450-4458.e6. DOI: 10.1016/j.jaip.2021.08.018. View

13.

Zhou S, Liu Y, Xue J, Tang J, Yu Q, Qu S . Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID-19 pandemic: A multicenter, two-arm, real-world study. Clin Transl Allergy. 2022; 12(3):e12122. PMC: 8886642. DOI: 10.1002/clt2.12122. View

14.

Chen Y, Zhu J, Lyu J, Xia Y, Ying Y, Hu Y . Association of Maternal Prepregnancy Weight and Gestational Weight Gain With Children's Allergic Diseases. JAMA Netw Open. 2020; 3(9):e2015643. PMC: 7489810. DOI: 10.1001/jamanetworkopen.2020.15643. View

15.

Cheng L, Chen J, Fu Q, He S, Li H, Liu Z . Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018; 10(4):300-353. PMC: 6021586. DOI: 10.4168/aair.2018.10.4.300. View

16.

Aarestrup F, Taketomi E, Galvao C, Gagete E, Nobrega Machado Arruda A, Alves G . Good clinical practice recommendations in allergen immunotherapy: Position paper of the Brazilian Association of Allergy and Immunology - ASBAI. World Allergy Organ J. 2022; 15(10):100697. PMC: 9513275. DOI: 10.1016/j.waojou.2022.100697. View

17.

Lao-Araya M, Sompornrattanaphan M, Kanjanawasee D, Tantilipikorn P . Allergen immunotherapy for respiratory allergies in clinical practice: A comprehensive review. Asian Pac J Allergy Immunol. 2023; 40(4):283-294. DOI: 10.12932/AP-260722-1418. View

18.

Wheatley L, Togias A . Clinical practice. Allergic rhinitis. N Engl J Med. 2015; 372(5):456-63. PMC: 4324099. DOI: 10.1056/NEJMcp1412282. View

19.

Roberts G, Pfaar O, Akdis C, Ansotegui I, Durham S, Gerth van Wijk R . EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2017; 73(4):765-798. DOI: 10.1111/all.13317. View

20.

Vogelberg C, Klimek L, Kruppert S, Becker S . Long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma. Clin Exp Allergy. 2023; 54(4):253-264. DOI: 10.1111/cea.14444. View